Table 1 Demographic characteristics and co-morbidities for the 84 virologically suppressed, HIV-infected patients entered in this study
| Â | All | NVP-XR | NVP-IR | P |
|---|---|---|---|---|
NÂ =Â 84 | NÂ =Â 35 | NÂ =Â 49 | ||
Age, mean years (± SD) | 41 (13) | 43 (12) | 40 (14) | 0.38 |
Gender, Male (%) | 72 (85.7) | 30 (85.7) | 42 (85.7) | 1.0 |
Body weight, kg (± SD) | 66.3 (12.3) | 67.1 (13.1) | 65.7 (11.8) | 0.62 |
Risk factor | ||||
 MSM, n (%) | 64 (82.1) | 29 (82.8) | 35 (71.4) | 0.22 |
 Heterosexual, n (%) | 10 (11.9) | 3 (8.6) | 7 (14.3) | 0.51 |
 IVDU, n (%) | 9 (10.7) | 3 (8.6) | 6 (12.2) | 0.73 |
 Vertical transmission, n (%) | 1 (1.1) | 0 (0) | 1 (2.0) | 1.0 |
Underlying disease | ||||
 Diabetes mellitus, n (%) | 3 (3.6) | 0 (0.0) | 3 (6.1) | 0.26 |
 CKD, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 Autoimmune disease, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 Chronic hepatitis B infection, n (%) | 8 (9.5) | 4 (11.4) | 4 (8.2) | 0.71 |
 Chronic hepatitis C infection, n (%) | 6 (7.1) | 1 (2.9) | 5 (10.2) | 0.39 |
Backbone of cART | Â | Â | Â | <0.001 |
 Kivexa, n (%) | 43 (51.2) | 27 (77.1) | 16 (32.7) | <0.001 |
 Combivir, n (%) | 27 (32.1) | 0 (0.0) | 27 (55.1) | <0.001 |
 TDF+ 3TC, n (%) | 8 (9.5) | 4 (11.4) | 4 (8.1) | 0.71 |
 DDI + 3TC, n (%) | 5 (6.0) | 4 (11.4) | 1 (2.0) | 0.16 |
 Kaletra, n (%) | 1 (1.2) | 0 (0.0) | 1 (2.0) | 1.0 |
Third drug of cARTa | ||||
 NVP-IR 200 mg twice daily, n (%) | 60 (71.4) | 11 (31.4) | 49 (100) | <0.001 |
 NVP-IR 400 mg once daily, n (%) | 24 (28.6%) | 24 (68.6) | 0 (0.0) | <0.001 |
Duration of continued virological suppression at entering this study, mean days (±SD) | 993 (758) | 1042 (565) | 959 (875) | 0.60 |
History of virological blip before entering this study, n (%) | 10 (11.9) | 3 (8.6) | 7 (14.3) | 0.51 |
Baseline CD4, mean cells/mm3 (±SD) | 489 (244) | 463 (193) | 508 (276) | 0.41 |
Patient follow-up, days (±SD) | 552 (170) | 555 (172) | 549 (170) | 0.86 |